Aspirin
prevents
Colorectal cancer
Aspirin
prevents
Colorectal cancer
9.6
ValidityScore
Valid or Invalid?
-
2021Meta-Analysis
-
Bhan C, Cao C, Cheng C, Guo Z, Han T, Ji Z, Ma S, Qu G, Sun C, Yan Y, Yang H, Zhang H, Zhou Q -
«Results: The result showed that aspirin use was not associated with incidence of Colorectal cancer (CRC) (RR 0.97; 95% CI 0.84-1.12; P = 0.66; I2 = 34%), aspirin use was found to be associated with reduced recurrence of colorectal adenomas (RR 0.83; 95% CI 0.72-0.95; P = 0.006; I2 = 63%) and reduced mortality of CRC (RR 0.79; 95% CI 0.64-0.97; P = 0.02; I2 = 14%). Subgroup analysis found a statistically significant association in low dose with a pooled RR of 0.85 (95% CI 0.74-0.99; P = 0.03; I2 = 31%).
Conclusions: This meta-analysis of randomized controlled trial data indicates that aspirin reduces the overall risk of recurrence and mortality of CRC and/or colorectal adenomas. Incidence of CRC was also reduced with low-dose aspirin. The emerging evidence on aspirin's cancer protection role highlights an exciting time for cancer prevention through low-cost interventions.» - Organism: Humans
- Strong Magnitude of Effect.
-
-
2020Meta-Analysis
-
Bosetti C, et al. -
Results
Regular aspirin use is associated with a reduced risk of colorectal cancer [RR = 0.73, 95% confidence interval (CI) = 0.69–0.78, 45 studies], squamous-cell esophageal cancer (RR = 0.67, 95% CI = 0.57–0.79, 13 studies), adenocarcinoma of the esophagus and gastric cardia (RR = 0.61, 95% CI = 0.49–0.77, 10 studies), stomach cancer (RR = 0.64, 95% CI = 0.51–0.82, 14 studies), hepato-biliary tract cancer (RR = 0.62, 95% CI = 0.44–0.86, five studies), and pancreatic cancer (RR = 0.78, 95% CI = 0.68–0.89, 15 studies), but not of head and neck cancer (RR = 0.94, 95% CI = 0.76–1.16, 10 studies). The associations are somewhat stronger in case-control than in cohort and nested case-control studies and are characterized by some between-study heterogeneity. Risk estimates are consistent across sex, geographical areas, and other selected covariates. For colorectal cancer, an aspirin dose between 75 and 100 mg/day conveys a risk reduction of 10%, and a dose of 325 mg/day of 35%. For all neoplasms, except head and neck cancer, inverse duration-risk relations with aspirin use are found.
Conclusion
The present comprehensive meta-analysis supports and further quantifies the inverse association between regular aspirin use and the risk of colorectal and other digestive tract cancer, including some rare ones. The favorable effect of aspirin increases with longer duration of use, and, for colorectal cancer, with increasing dose. - Organism: Humans
-
-
2016Meta-Analysis
-
Cao Y, Chan AT, Fuchs CS, Giovannucci EL, Nishihara R, Ogino S, Spiegelman D, Wang M, Willett WC, Wu K -
«Compared with nonregular use, regular aspirin use was associated with a lower risk for overall cancer (RR, 0.97; 95% CI, 0.94-0.99), which was primarily owing to a lower incidence of gastrointestinal tract cancers (RR, 0.85; 95% CI, 0.80-0.91), especially colorectal cancer (RR, 0.81; 95% CI, 0.75-0.88).»
- Organism: Humans
- Notable Magnitude of Effect.
-
#10.1001/jamaoncol.2015.6396, 26940135, Adult, Aged, Andrew T Chan, Aspirin / adverse effects, Aspirin / therapeutic use, Colorectal Neoplasms / epidemiology, Colorectal Neoplasms / pathology, Colorectal Neoplasms / prevention &, Female, Follow-Up Studies, Gastrointestinal Neoplasms / epidemiology, Gastrointestinal Neoplasms / pathology, Gastrointestinal Neoplasms / prevention &, Humans, MEDLINE, Male, Middle Aged, NCBI, NIH, NLM, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, PMC4900902, PubMed Abstract, Reiko Nishihara, Risk Assessment, Yin Cao, control, control -
Modified by
6 days ago
on Feb 21, 2021
ranked
added it
1 year ago
on Jan 10, 2020